Elevian develops medicines that restore youthful regenerative capacity with the potential to treat and prevent many age-related diseases.
Elevian has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in September 2021.
Elevian's investors include Prime Movers Lab, The Longevity Fund, Bold Capital Partners, Lauder Partners, For Good Ventures.
Elevian is headquartered in Allston, United States.
Elevian develops medicines that restore youthful regenerative capacity with the potential to treat and prevent many age-related diseases.
Elevian is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elevian — Funding & Investors." VCBacked, September 16, 2021, https://www.vcbacked.co/company/elevian. Accessed August 14, 2026.
VCBacked. (2021). Elevian — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/elevian
{{cite web |title=Elevian — Funding & Investors |url=https://www.vcbacked.co/company/elevian |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated